1 min read
Chief Medical Officer Summit -CMO 360°
Meet the Veristat team at Booth #3, April 17th and 18th in Boston
The Science-First CRO™ and Consultancy Ready to...
1 min read
There is much for companies to consider before submitting an investigational new drug (IND) application to FDA. Planning, collecting the appropriate data, and effectively communicating with regulatory bodies can all help companies overcome challenges in the pre-clinical stage of development and efficiently prepare for IND applications.
There is no single solution to a successful regulatory strategy and IND application. Companies that want to excel in the IND application process must have an integrated and expertly coordinated approach to IND planning and execution. With proper project and risk management as well as rapid decision-making, your company can prepare a quality and timely IND application.
Three of Veristat's Regulatory experts - Mara Holinger, Kevin Hennegan, and Erin Flynn - weigh in and share their thoughts on common IND misconceptions.
Read the full article to learn more about the following:
Explore related services:
1 min read
Apr 9, 2024 Veristat Events
Meet the Veristat team at Booth #3, April 17th and 18th in Boston
The Science-First CRO™ and Consultancy Ready to...
4 min read
Mar 22, 2024 Veristat Events
Don´t miss Veristat’s plenary presentation at the World Orphan Drug Congress (WODC), Boston, Thursday, April 25th at...